Continued disappointments with targeted agents in first-line therapy of advanced gastric cancers
Mené dans 27 pays sur 609 patients atteints d'un cancer de l'estomac ou de la jonction œso-gastrique MET+, cet essai de phase III évalue l'efficacité, du point de vue de la survie globale, et la toxicité de l'ajout du rilotumumab à une chimiothérapie combinant épirubicine, cisplatine et capécitabine en traitement de première ligne
Gastric and gastro-oesophageal cancers are the second leading cause of cancer death worldwide. Despite a concerted effort to characterise and understand the genomic landscape, only HER2 has been validated as a molecular target in the treatment of gastric and gastro-oesophageal cancer,1 highlighting the need to identify new therapeutic targets in the treatment for this disease
The Lancet Oncology , commentaire, 2016